Plasma Lipoprotein-associated Phospholipase A2 and Superoxide Dismutase Are Independent Predicators of Cognitive Impairment in Cerebral Small Vessel Disease Patients: Diagnosis and Assessment

Overview

Journal Aging Dis

Specialty Geriatrics

Date 2019 Aug 24

PMID 31440388

Citations 45

Authors

Shuzhen Zhu

Xiaobo Wei

Xiaohua Yang

Zifeng Huang

Zihan Chang

Fen Xie

Qin Yang

Changhai Ding

Wei Xiang

Hongjun Yang

Ying Xia

Zhong-Ping Feng

Hong-Shuo Sun

Midori A Yenari

Lin Shi

Vincent Ct Mok

Qing Wang

Affiliations

Soon will be listed here.

Abstract

Lipoprotein-associated phospholipase A2 (Lp-PLA2) and superoxide dismutase (SOD) are linked to regulating vascular/neuro-inflammation and stroke. Using a retrospective design, we investigated whether circulating Lp-PLA2 and SOD in cerebral small vessel disease (CSVD) patients were associated with cognitive impairment. Eighty-seven CSVD patients were recruited. Plasma Lp-PLA2 and SOD were determined, and cognitive status was measured by the Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA). The severity of white matter hypoerintensities (WMHs) in CSVD patients was rated according to Fazekas scales, and Lp-PLA2/SOD levels and MMSE/MoCA were compared. Multiple linear regressions were used to evaluate the relationship between Lp-PLA2 and SOD and the cognitive impairment. Ordinal logistic regression and generalized linear models (OLRGLMs) were applied to confirm whether Lp-PLA2 and SOD are independent risk factors for cognitive impairment in CVSD. Lp-PLA2 and SOD with mild or severe cognitive impairment were lower than those with normal congnition. Lp-PLA2 and SOD in CSVD patients with severe WMHs were significantly lower than those with mild or moderate WMH lesions. We noted positive linear associations of Lp-PLA and SOD with cognitive impairment in CSVD, independent of LDL-C. OLRGLMs confirmed that Lp-PLA2 and SOD were independent risk factors of cognitive impairment in CSVD. Lp-PLA2 and SOD are independently associated with cognitive impairment and WMH lesion, and may be useful for the rapid evaluation of cognitive impairment in CSVD. Lp-PLA2/SOD are modifiable factors that may be considered as therapeutic targets for preventing cognitive impairment in CSVD.

Citing Articles

Potential biomarkers for cerebral small vessel disease with cognitive impairment: a systematic review and meta-analysis.

Liao L, Huang W, Ma R, He X, Su M, Sha D Front Aging Neurosci. 2025; 16():1475571.

PMID: 39839309 PMC: 11747022. DOI: 10.3389/fnagi.2024.1475571.

Repetitive Transcranial Magnetic Stimulation Combined with Ginkgo Diterpene Lactone Meglumine Injection Recover Cognitive and Neurological Functions of Patients with Acute Ischemic Stroke.

Hao M, Wang X, Wei T, Sheng C Actas Esp Psiquiatr. 2025; 53(1):110-118.

PMID: 39801416 PMC: 11726206. DOI: 10.62641/aep.v53i1.1676.

Association between cerebral small vessel disease and plasma levels of LDL cholesterol and homocysteine: Implications for cognitive function.

Cheng Y, Li L, Lv Y, Zhang L, Chen W, Xu G J Med Biochem. 2024; 43(5):696-703.

PMID: 39712503 PMC: 11662953. DOI: 10.5937/jomb0-50100.

The Role of Lp-PLA2 as a Mediator Between Serum Magnesium and Zinc Levels and Cardiovascular Risk in Patients With Metabolic Syndrome.

Manik K, Joice P, Jagadal I, T K J, Samundeeswari V, Madompoyil B Cureus. 2024; 16(10):e72107.

PMID: 39574996 PMC: 11580104. DOI: 10.7759/cureus.72107.

What Are the Reliable Plasma Biomarkers for Mild Cognitive Impairment? A Clinical 4D Proteomics Study and Validation.

Hou Z, Sun A, Li Y, Song X, Liu S, Hu X Mediators Inflamm. 2024; 2024:7709277.

PMID: 38883967 PMC: 11178428. DOI: 10.1155/2024/7709277.

References

Packard C, OReilly D, Caslake M, McMahon A, Ford I, Cooney J . Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med. 2000; 343(16):1148-55. DOI: 10.1056/NEJM200010193431603. View

Noto H, Hara M, Karasawa K, Iso-O N, Satoh H, Togo M . Human plasma platelet-activating factor acetylhydrolase binds to all the murine lipoproteins, conferring protection against oxidative stress. Arterioscler Thromb Vasc Biol. 2003; 23(5):829-35. DOI: 10.1161/01.ATV.0000067701.09398.18. View

Oei H, van der Meer I, Hofman A, Koudstaal P, Stijnen T, Breteler M . Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005; 111(5):570-5. DOI: 10.1161/01.CIR.0000154553.12214.CD. View

van Oijen M, van der Meer I, Hofman A, Witteman J, Koudstaal P, Breteler M . Lipoprotein-associated phospholipase A2 is associated with risk of dementia. Ann Neurol. 2005; 59(1):139-44. DOI: 10.1002/ana.20721. View

Elkind M, Tai W, Coates K, Paik M, Sacco R . High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006; 166(19):2073-80. DOI: 10.1001/archinte.166.19.2073. View

Christensen H, Batterham P, Mackinnon A, Jorm A, Mack H, Mather K . The association of APOE genotype and cognitive decline in interaction with risk factors in a 65-69 year old community sample. BMC Geriatr. 2008; 8:14. PMC: 2488328. DOI: 10.1186/1471-2318-8-14. View

Cucchiara B, Messe S, Sansing L, Mackenzie L, Taylor R, Pacelli J . Lipoprotein-associated phospholipase A2 and C-reactive protein for risk-stratification of patients with TIA. Stroke. 2009; 40(7):2332-6. DOI: 10.1161/STROKEAHA.109.553545. View

Melkas S, Putaala J, Oksala N, Pohjasvaara T, Oksala A, Kaste M . Small-vessel disease relates to poor poststroke survival in a 12-year follow-up. Neurology. 2011; 76(8):734-9. DOI: 10.1212/WNL.0b013e31820db666. View

Gorelick P, Scuteri A, Black S, DeCarli C, Greenberg S, Iadecola C . Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011; 42(9):2672-713. PMC: 3778669. DOI: 10.1161/STR.0b013e3182299496. View

10.

Silva I, Mello A, Damasceno N . Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review. Lipids Health Dis. 2011; 10:170. PMC: 3204246. DOI: 10.1186/1476-511X-10-170. View

11.

Davidson J, Lockhart A, Amos L, Stirnadel-Farrant H, Mooser V, Sollberger M . Plasma lipoprotein-associated phospholipase A2 activity in Alzheimer's disease, amnestic mild cognitive impairment, and cognitively healthy elderly subjects: a cross-sectional study. Alzheimers Res Ther. 2012; 4(6):51. PMC: 3580460. DOI: 10.1186/alzrt154. View

12.

Wardlaw J, Smith E, Biessels G, Cordonnier C, Fazekas F, Frayne R . Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol. 2013; 12(8):822-38. PMC: 3714437. DOI: 10.1016/S1474-4422(13)70124-8. View

13.

Prins N, Scheltens P . White matter hyperintensities, cognitive impairment and dementia: an update. Nat Rev Neurol. 2015; 11(3):157-65. DOI: 10.1038/nrneurol.2015.10. View

14.

Lin J, Zheng H, Cucchiara B, Li J, Zhao X, Liang X . Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. Neurology. 2015; 85(18):1585-91. PMC: 4642142. DOI: 10.1212/WNL.0000000000001938. View

15.

Gomez-Marcos M, Blazquez-Medela A, Gamella-Pozuelo L, Recio-Rodriguez J, Garcia-Ortiz L, Martinez-Salgado C . Serum Superoxide Dismutase Is Associated with Vascular Structure and Function in Hypertensive and Diabetic Patients. Oxid Med Cell Longev. 2015; 2016:9124676. PMC: 4655282. DOI: 10.1155/2016/9124676. View

16.

Savas S, Kabaroglu C, Alpman A, Sarac F, Yalcin M, Parildar Z . No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin in Alzheimer's disease. Exp Gerontol. 2016; 77:1-6. DOI: 10.1016/j.exger.2016.01.014. View

17.

Kobylecki C, Afzal S, Nordestgaard B . Genetically Low Antioxidant Protection and Risk of Cardiovascular Disease and Heart Failure in Diabetic Subjects. EBioMedicine. 2016; 2(12):2010-5. PMC: 4703764. DOI: 10.1016/j.ebiom.2015.11.026. View

18.

Xu X, Zhang B, Lu K, Deng J, Zhao F, Zhao B . Prevention of Hippocampal Neuronal Damage and Cognitive Function Deficits in Vascular Dementia by Dextromethorphan. Mol Neurobiol. 2016; 53(5):3494-3502. DOI: 10.1007/s12035-016-9786-5. View

19.

Doody R, Demirovic J, Ballantyne C, Chan W, Barber R, Powell S . Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. Alzheimers Dement (Amst). 2016; 1(4):464-71. PMC: 4879494. DOI: 10.1016/j.dadm.2015.08.001. View

20.

Funderburg N, McComsey G, Kulkarni M, Bannerman T, Mantini J, Thornton B . Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine. 2016; 13:321-327. PMC: 5264242. DOI: 10.1016/j.ebiom.2016.10.009. View